eHealth, Inc. revised earnings guidance for the full year ending December 31, 2023. Total revenue is expected to be in the range of $439 million to $459 million compared to prior guidance of $420 million to $440 million. GAAP net loss is expected to be in the range of $46 million to $26 million compared to prior guidance of $55 million to $35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.84 USD | +5.04% | +8.96% | -33.03% |
05-24 | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
05-07 | EHealth Shares Jump After Q1 Net Loss Shrinks, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.03% | 170M | |
-4.04% | 60.72B | |
+10.43% | 54.26B | |
+3.91% | 25.62B | |
+23.16% | 24.98B | |
+15.66% | 8.69B | |
+26.08% | 6.46B | |
-6.19% | 4.09B | |
0.00% | 3.31B | |
+42.92% | 2.27B |
- Stock Market
- Equities
- EHTH Stock
- News eHealth, Inc.
- EHealth, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023